SynthesisLancet (London, England)2019

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Thomas A Zelniker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.